MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 10, 2006; DOI: 10.1124/mol.106.028167


0026-895X/07/7101-240-249$20.00
Mol Pharmacol 71:240-249, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.028167v1
71/1/240    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breedveld, P.
Right arrow Articles by Schellens, J. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breedveld, P.
Right arrow Articles by Schellens, J. H. M.

The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

Pauline Breedveld, Dick Pluim, Greta Cipriani, Femke Dahlhaus, Maria A. J. van Eijndhoven, Cornelia J. F. de Wolf, Annemieke Kuil, Jos H. Beijnen, George L. Scheffer, Gerrit Jansen, Piet Borst, and Jan H. M. Schellens

Departments of Experimental Therapy (P.Br., D.P., G.C., F.D., M.A.J.v.E., J.H.M.S.), Molecular Biology (C.J.F.d.W., A.K., P.Bo.), Pharmacy (J.H.B.), and Medical Oncology (J.H.B., J.H.M.S.), the Netherlands Cancer Institute, Amsterdam, the Netherlands; Departments of Rheumatology (G.J.) and Pathology (G.L.S.), VU University Medical Center, Amsterdam, the Netherlands; and Faculty of Pharmaceutical Sciences (J.B., J.H.M.S.), Utrecht University, Utrecht, the Netherlands

Some cellular uptake systems for (anti)folates function optimally at acidic pH. We have tested whether this also applies to efflux from cells by breast cancer resistance protein (BCRP; ABCG2), which has been reported to transport folic acid, methotrexate, and methotrexate di- and triglutamate at physiological pH. Using Spodoptera frugiperda-BCRP membrane vesicles, we showed that the ATP-dependent vesicular transport of 1 µM methotrexate by BCRP is 5-fold higher at pH 5.5 than at physiological pH. The transport of methotrexate was saturable at pH 5.5, with apparent Km and Vmax values of 1.3 ± 0.2 mM and 44 ± 2.5 nmol/mg of protein/min, respectively, but was linear with drug concentration at pH 7.3 up to 6 mM methotrexate. In contrast to recent reports, we did not detect transport of methotrexate diglutamate at physiological pH, but we did find transport at pH 5.5. We also found that 7-hydroxy-methotrexate, the major metabolite of methotrexate, is transported by BCRP both at physiological pH and (more efficiently) at low pH. The pH effect was also observed in intact BCRP-overexpressing cells: we found a 3-fold higher level of resistance to both methotrexate and the prototypical BCRP substrate mitoxantrone at pH 6.5 as at physiological pH. Furthermore, with MDCKII-BCRP monolayers, we found that resveratrol, which is a neutral compound at pH ≤ 7.4, is efficiently transported by BCRP at pH 6.0, whereas we did not detect active transport at pH 7.4. We conclude that BCRP transports substrate drugs more efficiently at low pH, independent of the dissociation status of the substrate.


Received June 25, 2006; accepted September 25, 2006

Address correspondence to: Dr. Jan H. M. Schellens, Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. E-mail: j.schellens{at}nki.nl




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
E Kis, T Nagy, M Jani, E Molnar, J Janossy, O Ujhellyi, K Nemet, K Heredi-Szabo, and P Krajcsi
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance
Ann Rheum Dis, July 1, 2009; 68(7): 1201 - 1207.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. L.H. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, D. R. de Waart, K. van de Wetering, C. M.M. van der Kruijssen, R. P.J. Oude Elferink, O. van Tellingen, and A. H. Schinkel
Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo
Clin. Cancer Res., May 1, 2009; 15(9): 3084 - 3093.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. L. Oostendorp, E. van de Steeg, C. M. M. van der Kruijssen, J. H. Beijnen, K. E. Kenworthy, A. H. Schinkel, and J. H. M. Schellens
Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors
Drug Metab. Dispos., April 1, 2009; 37(4): 917 - 923.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. van de Wetering, A. Burkon, W. Feddema, A. Bot, H. de Jonge, V. Somoza, and P. Borst
Intestinal Breast Cancer Resistance Protein (BCRP)/Bcrp1 and Multidrug Resistance Protein 3 (MRP3)/Mrp3 Are Involved in the Pharmacokinetics of Resveratrol
Mol. Pharmacol., April 1, 2009; 75(4): 876 - 885.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. S. Lagas, C. M. M. van der Kruijssen, K. van de Wetering, J. H. Beijnen, and A. H. Schinkel
Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone
Drug Metab. Dispos., January 1, 2009; 37(1): 129 - 136.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. L.H. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, O. van Tellingen, D. R. de Waart, R. P.J. Oude Elferink, K. van de Wetering, and A. H. Schinkel
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate
Clin. Cancer Res., December 15, 2008; 14(24): 8152 - 8160.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. de Wolf, R. Jansen, H. Yamaguchi, M. de Haas, K. van de Wetering, J. Wijnholds, J. Beijnen, and P. Borst
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Mol. Cancer Ther., September 1, 2008; 7(9): 3092 - 3102.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Marchetti, R. L. Oostendorp, D. Pluim, M. van Eijndhoven, O. van Tellingen, A. H. Schinkel, R. Versace, J. H. Beijnen, R. Mazzanti, and J. H. Schellens
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2
Mol. Cancer Ther., December 1, 2007; 6(12): 3307 - 3313.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. Glavinas, E. Kis, A. Pal, R. Kovacs, M. Jani, E. Vagi, E. Molnar, S. Bansaghi, Z. Kele, T. Janaky, et al.
ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions
Drug Metab. Dispos., September 1, 2007; 35(9): 1533 - 1542.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics